Kidney disease profoundly affects bone health in ways that go far beyond simple calcium deficiency. The kidneys play a central role in mineral metabolism — activating vitamin D, excreting excess phosphorus, and helping regulate parathyroid hormone (PTH) — and as kidney function declines, all of these processes are disrupted simultaneously, creating a complex set of bone and mineral disorders collectively called chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD encompasses impaired bone mineralization, bone loss, increased fracture risk, and vascular calcification — the latter of which contributes directly to the dramatically elevated cardiovascular mortality seen in kidney disease patients. This complication is present in some form in the majority of patients with stage 3 CKD and is nearly universal in dialysis patients. Understanding what CKD-MBD is, how it is diagnosed and monitored, and what treatments are available gives patients the knowledge they need to participate in their own management and reduce the risk of fractures and cardiovascular complications. For context on the cardiovascular consequences of mineral dysregulation, see the companion article on kidney disease and heart health, which covers vascular calcification in more detail.
How Kidney Disease Disrupts Mineral Metabolism and Bone
The normal regulation of calcium, phosphorus, and bone turnover involves a complex interplay between the kidneys, parathyroid glands, intestines, and bone — and CKD disrupts multiple steps in this system simultaneously. Understanding this mechanism helps explain why several different treatment approaches are often needed and why early intervention matters. Phosphorus retention: healthy kidneys excrete most of the dietary phosphorus that enters the bloodstream. As kidney function declines, phosphorus excretion decreases, and serum phosphorus levels rise (hyperphosphatemia). Elevated phosphorus binds calcium in the blood (forming insoluble calcium phosphate complexes), lowering ionized calcium levels. Elevated phosphorus also has direct toxic effects on blood vessel walls, promoting vascular calcification independently of calcium binding. Vitamin D deficiency: the kidneys contain the enzyme 1-alpha-hydroxylase, which converts the inactive form of vitamin D (25-hydroxyvitamin D, produced in the liver from sun-exposed skin) to the active form (1,25-dihydroxyvitamin D, also called calcitriol). As kidney function declines, this activation step fails — calcitriol deficiency develops, which reduces intestinal calcium absorption and impairs PTH suppression. Most CKD patients become calcitriol-deficient even if their dietary vitamin D intake is adequate, because the activation step requires functioning kidney tissue. Secondary hyperparathyroidism: the falling ionized calcium and falling calcitriol both stimulate the parathyroid glands to produce more PTH. PTH normally acts to raise serum calcium (by mobilizing calcium from bone, increasing kidney calcium reabsorption, and stimulating calcitriol production) — but in CKD, the kidney calcium reabsorption and calcitriol production responses are impaired, so PTH escalates without achieving its targets. The resulting chronically elevated PTH (secondary hyperparathyroidism) drives excess bone resorption, weakens bone architecture, and contributes to the characteristic CKD bone disease called osteitis fibrosa. FGF-23 elevation: fibroblast growth factor 23 (FGF-23), a phosphate-regulating hormone produced by osteocytes (bone cells), rises very early in CKD — often before other mineral abnormalities are detectable — as a compensatory attempt to increase phosphorus excretion. Elevated FGF-23 suppresses calcitriol production (compounding the vitamin D deficiency) and has direct pro-inflammatory and cardiovascular effects. FGF-23 elevation is now recognized as an independent predictor of cardiovascular events and mortality in CKD. Resulting bone disorders: the net effect of these disruptions on bone is complex and heterogeneous. Some patients develop high-turnover bone disease (osteitis fibrosa, driven by elevated PTH) with excess bone resorption, abnormal mineralization, and increased fracture risk. Others develop low-turnover bone disease (adynamic bone disease, particularly common in dialysis patients and those over-suppressed with calcitriol) with reduced bone formation and also increased fracture risk. Still others develop osteomalacia (softening of bone due to inadequate mineralization) or mixed lesions. The NIDDK patient guidance on CKD and bone disease is at the NIDDK CKD mineral and bone disorder page.
Monitoring Bone and Mineral Health in CKD
CKD-MBD monitoring involves a set of blood tests that track the key parameters of mineral metabolism. The frequency of monitoring increases as CKD advances and as treatment is initiated or adjusted. Phosphorus: serum phosphorus is monitored regularly in CKD stage 3–5. Target range in CKD is approximately 2.5–4.5 mg/dL (normal adult range); in dialysis patients, the target is typically 3.5–5.5 mg/dL. Hyperphosphatemia (elevated phosphorus) is common in advanced CKD and dialysis and requires dietary restriction and phosphate binders. Calcium: serum calcium (total or corrected for albumin) is measured alongside phosphorus. Both hypercalcemia (elevated calcium, which can occur from over-supplementation of calcium-containing phosphate binders or excessive active vitamin D) and hypocalcemia (from vitamin D deficiency or calcium-phosphate binding) need to be identified and managed. Parathyroid hormone (PTH): intact PTH (iPTH) is measured every 3–6 months in CKD stage 3–4 and every 1–3 months in CKD stage 5 and dialysis. Target PTH levels in CKD vary by stage: in dialysis patients, the KDIGO guidelines suggest maintaining PTH within approximately 2–9 times the upper limit of normal (approximately 150–600 pg/mL with the standard assay), recognizing that some degree of PTH elevation is desirable in dialysis to maintain bone turnover (over-suppression leads to adynamic bone disease). Vitamin D: 25-hydroxyvitamin D (calcidiol, the storage form) is measured to assess overall vitamin D sufficiency, typically with a target above 30 ng/mL. Active vitamin D (calcitriol or its analogues) levels are not routinely measured; prescribing decisions are based on PTH, calcium, and phosphorus rather than calcitriol levels. Alkaline phosphatase (ALP): bone-specific alkaline phosphatase reflects bone formation rate and is elevated in high-turnover bone disease (osteitis fibrosa). Total ALP is measured as part of routine chemistry panels; a markedly elevated ALP in the setting of high PTH is consistent with significant CKD bone disease. Bone mineral density (DXA scan): DEXA scanning is used to assess bone mineral density in CKD patients with fracture risk factors or those considering therapies that affect bone. Its interpretation in advanced CKD is complex because DEXA measures bone quantity but not the quality abnormalities (cortical porosity, architectural disruption) that characterize CKD bone disease. The KDIGO CKD-MBD guidelines are at the KDIGO CKD-MBD guidelines page.
Treatment of CKD-MBD: Dietary Restriction, Phosphate Binders, and Vitamin D
Treatment of CKD mineral and bone disorder targets the underlying abnormalities — elevated phosphorus, deficient vitamin D, elevated PTH — through a combination of dietary modification, pharmacological treatment, and (in some cases) parathyroid intervention. Dietary phosphorus restriction: reducing dietary phosphorus intake to approximately 800–1000 mg per day is the first step in managing hyperphosphatemia. Phosphorus is found in high concentrations in dairy products, nuts, legumes, whole grains, meat, fish, and poultry. Processed foods and fast foods contain significant phosphorus-based additives (orthophosphates and polyphosphates) that are more bioavailable than naturally occurring phosphorus — reducing ultra-processed food intake therefore reduces phosphorus burden even beyond what standard phosphorus counting captures. Working with a renal dietitian who is knowledgeable about phosphorus sources — including understanding which foods contain bioavailable phosphorus additives versus less-bioavailable phytate-bound phosphorus in whole foods — is important. The companion article on phosphorus and kidney disease covers dietary phosphorus management in detail. Phosphate binders: medications taken with meals that bind dietary phosphorus in the gut and prevent its absorption. Types include calcium-containing binders (calcium carbonate, calcium acetate — effective but increase total calcium load, which may contribute to vascular calcification in patients who are already hypercalcemic or have high calcium-phosphorus product); non-calcium binders including sevelamer (Renvela/Renagel — also lowers LDL cholesterol and is preferred in patients with vascular calcification or hypercalcemia), lanthanum carbonate (Fosrenol), and ferric citrate (which also provides iron). Phosphate binders must be taken with meals to be effective — the most common reason for inadequate phosphorus control is not taking the binder at the right time. Native vitamin D supplementation: cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2) are used to correct 25-hydroxyvitamin D deficiency (below 30 ng/mL). However, in advanced CKD, the kidneys cannot activate native vitamin D, so supplementing native vitamin D alone does not correct calcitriol deficiency. Regular monitoring is needed because native vitamin D supplementation should not drive 25-OHD levels excessively high. Active vitamin D analogues: calcitriol (1,25-dihydroxyvitamin D3), paricalcitol (Zemplar), and doxercalciferol (Hectorol) are active vitamin D forms that do not require kidney activation. They are used to directly suppress PTH when secondary hyperparathyroidism develops (PTH significantly above target despite correction of phosphorus and native vitamin D deficiency). Active vitamin D increases intestinal calcium and phosphorus absorption, so phosphorus and calcium must be well-controlled before starting. Calcimimetics: cinacalcet (Sensipar) and etelcalcetide (Parsabiv, IV for dialysis) increase the sensitivity of the parathyroid gland calcium-sensing receptor, suppressing PTH production without raising calcium or phosphorus. They are used in secondary hyperparathyroidism resistant to vitamin D therapy, particularly in dialysis patients with elevated calcium. Parathyroidectomy: surgical removal of one or more parathyroid glands is required in severe tertiary hyperparathyroidism (autonomous PTH production that does not respond to medical management). It is associated with dramatic PTH reduction and improvement in bone pain, pruritus, and mineral balance. The NKF provides patient resources on bone health and kidney disease at the NKF kidney health page. The StatPearls CKD-MBD reference is at the StatPearls resource.
Fracture Risk in CKD and Protecting Bone Strength
Fracture risk is substantially elevated in CKD patients compared to the general population — dialysis patients have fracture rates 3–4 times higher than age-matched individuals without kidney disease, and CKD stage 3–4 patients also have significantly elevated risk. Understanding the specific risk factors and protective measures is essential for patients who want to reduce their fracture risk. Why CKD patients fracture more: the bone quality abnormalities of CKD-MBD — high-turnover osteitis fibrosa, low-turnover adynamic bone disease, and osteomalacia — all reduce bone strength. Dialysis patients additionally have higher fall risk due to muscle weakness, hypotension, and fatigue. The combination of impaired bone quality and increased fall risk produces a dramatically higher fracture incidence. Standard osteoporosis treatments in CKD: bisphosphonates (alendronate, risedronate, zoledronic acid), which are the mainstay of osteoporosis treatment in the general population, are recommended with caution in CKD. They are generally avoided in patients with eGFR below 30–35 mL/min because they are not well-studied in advanced CKD and may accumulate or worsen bone disease; at higher eGFR levels (above 30–45), they may be appropriate with careful monitoring. Denosumab (Prolia) — a RANK-L inhibitor that reduces osteoclast activity — does not require kidney-based elimination and is an option in advanced CKD, though it can cause severe hypocalcemia in CKD patients, requiring careful calcium and vitamin D management before and during treatment. Maintaining muscle strength and fall prevention: preventing falls is as important as improving bone strength in CKD patients with fracture risk. Regular physical activity — weight-bearing exercise in particular — helps maintain muscle mass and bone density. Balance training and physical therapy reduce fall risk. Environmental modifications (grab bars, non-slip mats, adequate lighting) reduce the consequences of balance impairment. Calcium supplementation: routine high-dose calcium supplementation in CKD patients is not recommended — most CKD patients already have elevated calcium-phosphorus product risk, and calcium supplementation can promote vascular calcification. Correcting calcitriol deficiency with active vitamin D analogues is a more targeted approach to improving intestinal calcium absorption. Dietary calcium from low-phosphorus sources (avoiding high-phosphorus dairy) is generally preferable to supplements. For patients managing kidney disease across multiple complications — anemia, high blood pressure, and bone health simultaneously — the article on kidney disease and anemia covers the overlap between mineral metabolism and red blood cell production in CKD, and the kidney disease and high blood pressure article covers the RAAS interactions with mineral metabolism.
Sources: NIDDK CKD Mineral and Bone Disorder · KDIGO CKD-MBD Guidelines · National Kidney Foundation · StatPearls: Nephrology
Vascular Calcification: When Mineral Disorder Damages Blood Vessels
Vascular calcification — the deposition of calcium-phosphate crystals in the walls of blood vessels and heart valves — is one of the most clinically significant consequences of CKD-MBD and a major contributor to the dramatically elevated cardiovascular mortality seen in kidney disease patients. It is not simply a passive accumulation of mineral but an active, regulated process driven by the same mechanisms that impair bone mineralization in CKD. Mechanisms of vascular calcification in CKD: elevated serum phosphorus directly promotes calcification of vascular smooth muscle cells by triggering them to undergo a process resembling osteoblast differentiation — they begin producing bone matrix proteins and promoting mineral deposition in the vessel wall. Elevated calcium-phosphorus product amplifies this process. The very high FGF-23 levels in advanced CKD, and the secondary hyperparathyroidism-driven release of alkaline phosphatase from bone, both contribute to a pro-calcification environment. Calcification inhibitors — including matrix Gla protein, fetuin-A, and pyrophosphate — are reduced or impaired in CKD, removing a natural brake on this process. Consequences of vascular calcification: calcification stiffens arterial walls, reducing their ability to absorb the pulse wave of cardiac contraction — elevating systolic blood pressure and pulse pressure, increasing cardiac afterload, and accelerating LVH. Calcification of the coronary arteries directly increases risk of myocardial infarction. Calcification of heart valves (particularly the aortic valve) causes functional valvular disease. Medial calcification (calcium in the muscular wall of arteries, as opposed to intimal/atherosclerotic plaques) is particularly common in CKD and dialysis and results in the rigid “water pipe” arteries that make blood pressure control difficult and reduce coronary perfusion during diastole. Vascular calcification scoring: lateral abdominal X-ray (abdominal aortic calcification score) and cardiac CT calcium scoring are used to quantify vascular calcification burden in CKD patients with cardiovascular risk. High calcification scores are associated with significantly worse cardiovascular outcomes and inform decisions about treatment intensity. Managing vascular calcification risk: controlling phosphorus (through diet and binders), avoiding calcium-based phosphate binders in patients with existing calcification or elevated calcium, maintaining optimal vitamin D status without over-supplementation, and controlling blood pressure are the primary strategies for limiting calcification progression. Non-calcium phosphate binders (sevelamer, lanthanum carbonate) are preferred in patients with known vascular calcification or high calcium-phosphorus product because they effectively bind phosphorus without adding to the calcium load. The NIDDK overview of CKD-MBD and vascular complications is at the NIDDK CKD mineral and bone disorder page.
What Patients With CKD Should Know About Their Bone and Mineral Labs
Understanding the key lab values relevant to bone and mineral health in CKD helps patients engage actively in their care and recognize when additional discussion or treatment adjustment is warranted. Know your phosphorus level and target: in CKD stages 3–5, serum phosphorus is typically checked every 3–6 months (more frequently in advanced CKD or when treatment is being adjusted). Phosphorus above 4.5 mg/dL in non-dialysis CKD, or above 5.5 mg/dL in dialysis patients, is generally considered above target and may require dietary adjustment, new or adjusted phosphate binders, or more frequent dialysis. Know your PTH level and what it means: PTH in the normal range for a healthy individual (10–65 pg/mL with most assays) may actually be low-normal for a CKD patient — some degree of PTH elevation is normal and even desirable in later CKD stages to maintain bone turnover. Ask your nephrologist what PTH target range applies to your specific CKD stage. Take phosphate binders correctly: phosphate binders only work when taken with food — they bind dietary phosphorus in the gut during digestion. Taking them between meals or on an empty stomach provides no benefit. If you are prescribed a binder, take it with every meal and every snack that contains significant phosphorus. Understand the risks of stopping phosphate binders: some patients stop taking phosphate binders because they are inconvenient or because they feel their diet is “good enough.” However, dietary restriction alone is rarely sufficient in advanced CKD; the combination is necessary for adequate phosphorus control. Ask about vitamin D status: 25-hydroxyvitamin D levels should be checked annually in CKD. If below 30 ng/mL, supplementation with native vitamin D is indicated. If PTH is elevated despite adequate native vitamin D, active vitamin D (calcitriol or a synthetic analogue) may be recommended. Report bone pain, fractures, or muscle weakness promptly: persistent bone pain, unexplained fractures from minor trauma, or progressive muscle weakness in a CKD patient may indicate significant CKD-MBD requiring re-evaluation and treatment adjustment. These symptoms should not be dismissed as “just part of kidney disease” without appropriate investigation. For guidance on the full range of kidney disease management, including how CKD-MBD interacts with other complications, see the article on slowing kidney disease progression. Patients with both CKD-MBD and anemia face overlapping mineral and erythropoiesis concerns — see the companion article on kidney disease and anemia for context on how secondary hyperparathyroidism affects both bone and red blood cell production.
Pruritus and Itching in CKD-MBD: The Skin Manifestation of Mineral Disorder
Chronic pruritus — persistent generalized itching — is one of the most distressing and underappreciated symptoms in advanced CKD, particularly in dialysis patients, and has a significant relationship to CKD-MBD. Uremic pruritus (also called CKD-associated pruritus) affects 40–70% of hemodialysis patients and is associated with poor sleep, depression, reduced quality of life, and — in some studies — increased mortality. While the exact mechanisms are complex and incompletely understood, dysregulated mineral metabolism (elevated phosphorus, high PTH, elevated calcium-phosphorus product) is among the factors associated with more severe pruritus, along with immune dysregulation and abnormal opioid signaling in the skin. Management of CKD-associated pruritus: improving phosphorus and PTH control through dietary restriction, optimized binder therapy, and appropriate vitamin D and calcimimetic management is an important first step. Adequate dialysis adequacy (achieving the prescribed dialysis dose) reduces the uremic toxin burden. Moisturizing emollient creams reduce dry skin contribution. Gabapentin or pregabalin at kidney-adjusted doses have evidence for symptom reduction. Nalfurafine (a kappa opioid receptor agonist, approved in Japan and some other countries) is the most specific pharmacological treatment. Difelikefalin (Korsuva, a kappa opioid receptor agonist approved in the US for dialysis-associated pruritus in 2021) provides significant symptom relief in clinical trials. If pruritus is not being adequately addressed, patients should specifically raise it as a management priority — it should not be accepted as an inevitable, untreatable part of dialysis. The connection between CKD-MBD and pruritus reinforces the importance of optimal mineral metabolism management, which benefits multiple symptoms and outcomes simultaneously. For patients who want to understand how all of the CKD complications interconnect — bone health, anemia, cardiovascular disease, hypertension, and more — the article on kidney failure treatment options provides an overview of the clinical landscape for patients with advanced kidney disease, and the dialysis overview guide covers how dialysis affects all of these complications in patients who have reached kidney failure.
My nephrologist just prescribed sevelamer for my CKD stage 4 and I wasn’t sure why it was better than calcium carbonate. This article explains it so clearly — I had no idea that calcium-based binders could make vascular calcification worse. Really appreciate the detail on how to take binders correctly with meals too, that’s something I wasn’t doing consistently.
Thank you, Margaret — you’ve identified one of the most important practical distinctions in CKD-MBD management. Sevelamer is preferred over calcium carbonate specifically when there’s existing vascular calcification, high calcium-phosphorus product, or hypercalcemia, because adding more calcium in those situations can worsen the calcification process. Your point about taking binders with meals is crucial — it’s one of the most common reasons phosphorus stays elevated despite being prescribed a binder. Consistent timing with every meal and significant snack makes a real difference in how effective they are.
I’ve been on dialysis for two years and CKD-MBD is something my care team talks about constantly but no one had explained the full picture to me before — FGF-23, the whole cascade of how phosphorus retention triggers everything else. The section on pruritus was also eye-opening because I deal with that constantly and didn’t connect it to my mineral levels. Going to bring this up at my next dialysis session.